MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Does Sarepta Therapeutics' Director Share Sale Signal to Investors

2 hours ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Does a CAO's Share Sale and Resignation Signal for Enhabit (EHAB) Investors

2 days ago

What Signal Does Director Lewis Clunet R.'s Recent SUI Share Sales Send

1 week ago

What's Behind Western Digital's SanDisk Share Sale

3 weeks ago

What Does a $1.1 Million CEO Stock Sale Signal for NextNav Investors

1 week ago

Is It Time To Sell Tesla Stock?

Analysis suggests investors may consider divesting from TSLA stock.

TSLA

Stock News•4 days ago

Director Sells 10,000 Shares of this Semiconductor Stock Down 25%. Should Investors Panic?

A director indirectly sold 10,080 shares of the semiconductor stock on Feb. 3, 2026, for ~$451.1K at $44.75/share. This sale reduced indirect ownership to zero, representing 1.72% of prior holdings.

POWI

Stock News•2 weeks ago

Sarepta Therapeutics, Inc. $SRPT Stock Position Lowered by AXQ Capital LP

AXQ Capital LP lowered its stake in Sarepta Therapeutics (SRPT) by 72.8% during the quarter, reducing its holding to 14,619 shares after selling 39,088 shares.

SRPT

Stock News•1 months ago

FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders

Halper Sadeh LLC investigates the proposed sale of Amicus Therapeutics (FOLD) to BioMarin Pharmaceutical for $14.50 per share. The law firm is examining if this transaction price is fair for Amicus sh...

FOLD